Peer Review History

Original SubmissionApril 23, 2022
Decision Letter - Sathishkumar V E, Editor

PONE-D-22-12003Changes in Key Recruitment Performance Metrics from 2008-2019 in Industry-sponsored Phase III Clinical Trials Registered at ClinicalTrials.govPLOS ONE

Dear Dr. Ali,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 30 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Sathishkumar V E

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"No funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. 

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. Please upload a new copy of Figures 3, 4 and 6 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/"" https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Comments to authors

Interesting paper but I could do with less statistical analysis and significance testing.

The generic question of interest is whether the drug industry is doing less trials over time. That is true from your results for multicenter trials but is it true overall for all industry sponsored trials?

My horseback counts from ClinicalTrials.gov for industry sponsored trials completed 2008-2019 is 64,537 and 15,517 for multicenter trials. Counts corresponding to your Table 1 for all industry sponsored trials are 20,092, 21,297, and 23,146 and for multicenter trials were 4,633, 5,090, and 5,794. You would do well with an introduction as to how you get from these numbers to those focused upon in your paper and also if these results reinforce your conclusions.

Curtis Meinert

Reviewer #2: Add related works as a separate section

Contributions of the research can be added at the end of introduction section

Conclusion should be added at the end of the manuscript providing overall summary of the manuscript

Provide clear images for all the Figures

Line 188, As seen in figure 2b, trial duration increased significantly pairwise between all three time intervals. Significantly pairwise?

If possible add Exploratory Data Analysis

Which users benefit from this study?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Usha Moorthy

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Re: PONE-D-22-12003 “Changes in Key Recruitment Performance Metrics from 2008-2019 in Industry-sponsored Phase III Clinical Trials Registered at ClinicalTrials.gov” by Brøgger-Mikkelsen et al.

Dear Editor-in-Chief

Thank you for giving us the opportunity to revise our paper and for the valuable suggestions from the reviewers. We have revised the paper according to the suggestions and issues raised.

Journal requirements:

Comment 1:

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Author response:

The manuscript has been revised carefully to meet PLOS ONE’s style requirements. We hope the manuscript is suitable for PLOS ONE now.

Comment 2:

Thank you for stating the following financial disclosure:

"No funders had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Author response:

The authors received no specific funding for this work. This statement has been added to the cover letter and thank you for changing the online submission on our behalf.

Comment 3:

We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Author response:

The link to all raw data is https://aact.ctti-clinicaltrials.org/connect. All the data is publicly available and with use of the provided link it is possible to get access to data used for analyses in the present manuscript.

Comment 4:

Please upload a new copy of Figures 3, 4 and 6 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/"" https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

Author response:

A new copy of figure 3, 4, and 6 has been provided in the required format.

Comment 5:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Author response:

The reference list has been reviewed to ensure it is complete and correct.

Reviewers' comments:

Reviewer #1:

Comment 1:

Interesting paper but I could do with less statistical analysis and significance testing.

The generic question of interest is whether the drug industry is doing less trials over time. That is true from your results for multicenter trials but is it true overall for all industry sponsored trials?

Author response:

Thanks for rising this interesting comment. Our results suggest that there is a reduction in multicenter trials; however, this is not true for all industry sponsored trials. It would be interesting to examine that more in the future. We have elaborated this issue in the section of limitation.

Comment 2:

My horseback counts from ClinicalTrials.gov for industry sponsored trials completed 2008-2019 is 64,537 and 15,517 for multicenter trials. Counts corresponding to your Table 1 for all industry sponsored trials are 20,092, 21,297, and 23,146 and for multicenter trials were 4,633, 5,090, and 5,794. You would do well with an introduction as to how you get from these numbers to those focused upon in your paper and also if these results reinforce your conclusions.

Author response:

Thanks for this comment. We have not included all industry-sponsored trials but only phase III trials with a drug as an intervention. We have emphasized that in the last section of introduction, first section of methods, and first section of discussion.

Reviewer #2:

Comment 1:

Add related works as a separate section

Author response:

Related work has been added as a separate section in the discussion.

Comment 2:

Contributions of the research can be added at the end of introduction section

Author response:

Author contribution has been added at the end of introduction.

Comment 3:

Conclusion should be added at the end of the manuscript providing overall summary of the manuscript

Author response:

Thank you for this comment. Conclusion section has been added at the end of the manuscript and revised to provide an overall summary of the manuscript.

Comment 4:

Provide clear images for all the Figures

Author response:

Thanks for making us ware of it. Clear images for all the figures have been provided.

Comment 5:

Line 188, As seen in figure 2b, trial duration increased significantly pairwise between all three time intervals. Significantly pairwise?

If possible add Exploratory Data Analysis

Author response:

Thank you for this comment. We acknowledge that the sentence may be confusing. The sentence has been rephrased and “pairwise” has been deleted.

Further, we recognize the merit of exploratory data analysis, but for the purpose of this study, we believe that our aggregate data analysis in the tables and figures represents data well.

Comment 6:

Which users benefit from this study?

Author response:

Thanks for this interesting question. Researchers and academics trying to understand recruitment patterns would benefit from this work. Private recruitment companies will also benefit from better understanding of changes in the recruitment over time.

Looking forward to hearing from you,

Yours sincerely

Zarqa Ali, MD PhD

Dept. of Dermatology

Bispebjerg Hospital

DK-2400 København NV

Zarqa_ali@hotmail.com

Attachments
Attachment
Submitted filename: response letter.docx
Decision Letter - Sathishkumar V E, Editor

Changes in Key Recruitment Performance Metrics from 2008-2019 in Industry-sponsored Phase III Clinical Trials Registered at ClinicalTrials.gov

PONE-D-22-12003R1

Dear Dr. Ali,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Sathishkumar V E

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Usha Moorthy

**********

Formally Accepted
Acceptance Letter - Sathishkumar V E, Editor

PONE-D-22-12003R1

Changes in Key Recruitment Performance Metrics from 2008-2019 in Industry-sponsored Phase III Clinical Trials Registered at ClinicalTrials.gov

Dear Dr. Ali:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sathishkumar V E

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .